Myriad Genetics | MYGN - Selling And Administration Expenses


Myriad Genetics reported $122.3M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Agilent USD 475M 10M Jun/2026
Becton, Dickinson and Co. USD 1.26B 48M Jun/2026
Bio-Rad Laboratories USD 212M 400K Jun/2026
Bruker USD 238.9M 3.2M Jun/2026
Danaher USD 2.07B 212M Jun/2026
Illumina USD 273M 1000K Jun/2026
J&J USD 6.42B 381M Jun/2026
Mettler Toledo International USD 263.33M 5.01M Jun/2026
Myriad Genetics USD 122.3M 6.7M Dec/2025
OraSure Technologies USD 13.21M 3.29M Dec/2025
Pacific Biosciences Of California USD 37.24M 25.68M Dec/2025
Quest Diagnostics USD 529M 25M Jun/2026
Quidel USD 189.7M 9.6M Jun/2026
Repligen USD 76.62M 82K Jun/2026
Revvity USD 278.58M 24.69M Jun/2026
Standard Biotools USD 18.61M 2.94M Mar/2026
Thermo Fisher Scientific USD 1.91B 111M Jun/2026
Veracyte USD 55.71M 4.87M Jun/2026
Waters USD 405M 11M Jun/2026